



Supplementary Figure 1 Comparison of the serum levels of three differentially expressed proteins between the patients after dapagliflozin treatments and the control subjects with diet and excise alone. The levels of myeloperoxidase, alpha II B integrin, and podocalyxin proteins in serum samples of the indicated patients were evaluated by enzyme linked immunosorbent assay. $n = 40$ for the dapagliflozin treatment group; $n = 20$ for the control diet and excise alone group. MPO: Myeloperoxidase; PCX: Podocalyxin.

Supplementary Table 1 Pearson correlation analysis between the levels of alpha II B integrin, podocalyxin, and myeloperoxidase proteins and clinical indexes in patients before and after dapagliflozin treatments

	MPO		Integrin α II β		PCX	
	r	P value	r	P value	r	P value
TG	0.191	0.128	0.084	0.506	0.009	0.943
LDL-C	0.232	0.063	0.152	0.228	0.230	0.065
HDL-C	-0.020	0.873	-0.075	0.552	0.119	0.343
ApoA1	-0.027	0.830	0.060	0.635	0.063	0.681
ApoB100	-0.080	0.524	-0.361	0.003	-0.246	0.048
CRP	0.267	0.032	0.162	0.197	0.098	0.438
HbA1c	0.183	0.144	0.155	0.218	0.067	0.596
HCY	-0.099	0.431	-0.224	0.073	-0.139	0.268
RBP	-0.352	0.004	-0.083	0.509	-0.102	0.420
NEFA	0.023	0.856	-0.048	0.706	-0.173	0.168
FCP	-0.006	0.962	-0.002	0.988	-0.035	0.781
TC	0.085	0.502	-0.114	0.365	0.033	0.795
FINS	-0.074	0.557	-0.188	0.135	-0.205	0.101
FBG	-0.089	0.481	-0.075	0.551	-0.267	0.031
HOMA2-B	-0.083	0.473	0.187	0.104	0.076	0.548
HOMA2-S%	0.181	0.116	0.042	0.720	0.066	0.567
HOMA-IR	-0.130	0.259	-0.054	0.639	-0.051	0.661

MPO: Myeloperoxidase; PCX: Podocalyxin; BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; TG: Triglycerides; LDL: Low-density lipoprotein; HDL: High-density lipoprotein; APOA1: Apolipoprotein A1; ApoB100: Apolipoprotein B100; CRP: C-reactive protein; FBG: Fasting blood glucose; HbA1c: Hemoglobin A1c; THCY: Homocysteine; RBP4: Retinol binding protein 4; NEFA: Non-esterified fatty acids; FCP: Fasting C-peptide; TC: Total cholesterol; FINS: Fasting

plasma insulin level; HOMA2-B: Homeostatic model assessment-beta cell; HOMA2-S%: Homeostatic model assessment-insulin sensitivity; HOMA2-IR: Homeostatic model assessment-insulin resistance.